SEC Form 4 · accession 0001250853-19-000041
Kindred Biosciences, Inc. · KIN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ernest Mario
Director
Period of report
Feb 1, 2019
Accepted (ET)
Feb 5, 2019 · 5:42 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001561743
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $9.91 | Feb 1, 2019 | A | 49,000 | A | — | Jan 31, 2029 | Common Stock | 49,000 | 49,000 | D |
Explanation of responses
- F1The option will vest in four equal quarterly installments from the option grant date.